Vericel Stock Forecast, Price & News

+2.14 (+4.32 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.10 million shs
Average Volume624,110 shs
Market Capitalization$2.41 billion
P/E Ratio287.18
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

Vericel logo

About Vericel

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.04 out of 5 stars

Medical Sector

497th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

74th out of 193 stocks

Analyst Opinion: 1.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Vericel (NASDAQ:VCEL) Frequently Asked Questions

Is Vericel a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vericel stock.
View analyst ratings for Vericel
or view top-rated stocks.

What stocks does MarketBeat like better than Vericel?

Wall Street analysts have given Vericel a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vericel wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vericel's next earnings date?

Vericel is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Vericel

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) announced its quarterly earnings results on Tuesday, August, 3rd. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.08). The biotechnology company had revenue of $39.52 million for the quarter, compared to analysts' expectations of $36.78 million. Vericel had a trailing twelve-month return on equity of 6.49% and a net margin of 5.78%. Vericel's revenue for the quarter was up 97.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.18) earnings per share.
View Vericel's earnings history

How has Vericel's stock been impacted by Coronavirus (COVID-19)?

Vericel's stock was trading at $12.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VCEL shares have increased by 327.9% and is now trading at $51.69.
View which stocks have been most impacted by COVID-19

What guidance has Vericel issued on next quarter's earnings?

Vericel updated its FY 2021 earnings guidance on Wednesday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $168 million-$171 million, compared to the consensus revenue estimate of $166.91 million.

What price target have analysts set for VCEL?

6 analysts have issued 12-month price targets for Vericel's stock. Their forecasts range from $31.00 to $65.00. On average, they anticipate Vericel's stock price to reach $50.00 in the next twelve months. This suggests that the stock has a possible downside of 3.3%.
View analysts' price targets for Vericel
or view top-rated stocks among Wall Street analysts.

Who are Vericel's key executives?

Vericel's management team includes the following people:
  • Dominick C. Colangelo, President, Chief Executive Officer & Director
  • Michael Halpin, Chief Operating Officer
  • Joseph A. Mara, Treasurer, Chief Financial & Accounting Officer
  • Jonathan Mark Hopper, Chief Medical Officer
  • Sean C. Flynn, Secretary, Vice President & General Counsel

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel CEO Nick Colangelo on Nick Colangelo has an approval rating of 49% among Vericel's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Vericel's key competitors?

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Momo (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.02%), Brown Capital Management LLC (9.84%), Vanguard Group Inc. (6.50%), State Street Corp (4.74%), Macquarie Group Ltd. (4.23%) and Federated Hermes Inc. (3.54%). Company insiders that own Vericel stock include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, Robert L Md Zerbe and Sean C Flynn.
View institutional ownership trends for Vericel

Which major investors are selling Vericel stock?

VCEL stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, BlackRock Inc., Invesco Ltd., State Street Corp, Next Century Growth Investors LLC, FMR LLC, Goldman Sachs Group Inc., and Lisanti Capital Growth LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, and Sean C Flynn.
View insider buying and selling activity for Vericel
or view top insider-selling stocks.

Which major investors are buying Vericel stock?

VCEL stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Conestoga Capital Advisors LLC, Fisher Asset Management LLC, Castleark Management LLC, JPMorgan Chase & Co., Dimensional Fund Advisors LP, Federated Hermes Inc., and First Trust Advisors LP.
View insider buying and selling activity for Vericel
or or view top insider-buying stocks.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $51.69.

How much money does Vericel make?

Vericel has a market capitalization of $2.41 billion and generates $124.18 million in revenue each year. The biotechnology company earns $3.04 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Vericel have?

Vericel employs 273 workers across the globe.

When was Vericel founded?

Vericel was founded in 1989.

What is Vericel's official website?

The official website for Vericel is

Where are Vericel's headquarters?

Vericel is headquartered at 64 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (800) 556-0311 or via email at [email protected]

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.